Oculis Holding AG (FRA:CR5) ROE % Adjusted to Book Value : -15.17% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG ROE % Adjusted to Book Value?

Oculis Holding AG's ROE % for the quarter that ended in Mar. 2024 was -73.56%. Oculis Holding AG's PB Ratio for the quarter that ended in Mar. 2024 was 4.85. Oculis Holding AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -15.17%.

Oculis Holding AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Oculis Holding AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG ROE % Adjusted to Book Value Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-57,016.05

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial							-	-11.60	-18.49	-13.80	-15.17

Competitive Comparison of Oculis Holding AG's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Oculis Holding AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's ROE % Adjusted to Book Value falls into.

Oculis Holding AG ROE % Adjusted to Book Value Calculation

Oculis Holding AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-209,248.89%	/	3.67
	=	-57,016.05%

Oculis Holding AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-73.56%	/	4.85
	=	-15.17%

Oculis Holding AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (FRA:CR5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

OCS:USA OCS:Iceland

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines